BRIEF published on 07/15/2026 at 17:50, 1 month 28 days ago Median Technologies publie un rapport sur son contrat de liquidités pour le premier semestre 2026 Contrat De Liquidité Ressources Financières Transactions Sur Actions Technologies Médianes S1 2026
BRIEF published on 07/15/2026 at 17:50, 1 month 28 days ago Median Technologies Reports on Liquidity Contract for H1 2026 Liquidity Contract Financial Resources Share Transactions Median Technologies H1 2026
PRESS RELEASE published on 07/15/2026 at 17:45, 1 month 28 days ago Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract Median Technologies liquidity contract statement for the first half of 2026 reveals resources in the account and transactions made. TP ICAP (Europe) manages the liquidity contract Liquidity Contract Transactions TP ICAP Median Technologies First Half 2026
BRIEF published on 07/03/2026 at 07:05, 2 months 9 days ago Median Technologies' eyonis® LCS receives CE marking Artificial Intelligence Cancer Screening Median Technologies CE Marking Eyonis® LCS
BRIEF published on 07/03/2026 at 07:05, 2 months 9 days ago Median Technologies’ eyonis® LCS Secures CE Marking Early Detection CE Marking European Union Lung Cancer Screening AI-based Diagnostics
BRIEF published on 07/03/2026 at 07:05, 2 months 9 days ago Le système eyonis® LCS de Median Technologies obtient le marquage CE Marquage CE Union Européenne DÉTECTION PRÉCOCE Diagnostics Basés Sur L'IA Dépistage Du Cancer Du Poumon
BRIEF published on 07/03/2026 at 07:05, 2 months 9 days ago Eyonis® LCS de Median Technologies reçoit le marquage CE Marquage CE Intelligence Artificielle Median Technologies Eyonis® LCS Dépistage Cancer
PRESS RELEASE published on 07/03/2026 at 07:00, 2 months 9 days ago Inside Information / Other news releases Median Technologies' eyonis® LCS obtains CE Marking under new European Medical Device Regulation, enabling commercial launch across the EU. AI-based software empowers lung cancer screening programs for earlier diagnosis Median Technologies CE Marking AI-based Software Lung Cancer Screening Eyonis® LCS
PRESS RELEASE published on 07/03/2026 at 07:00, 2 months 9 days ago Informations privilégiées / Autres communiqués Median Technologies obtient le marquage CE pour eyonis® LCS, logiciel IA pour dépistage cancer du poumon, en Europe. eyonis® LCS offre performances uniques pour diagnostic précoce Marquage CE Dépistage Median Technologies Cancer Du Poumon Eyonis® LCS
BRIEF published on 06/03/2026 at 19:59, 3 months 9 days ago Median Technologies Raises €50 Million in Capital Increase Capital Increase Shareholder Base Market Oversubscription Eyonis® Deployment AI-based Diagnostics
Published on 09/12/2026 at 02:35, 1 day 4 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 1 day 7 hours ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 21:25, 1 day 9 hours ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day 13 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 13 hours 2 minutes ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 23 hours 22 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 1 day 8 hours ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 day 8 hours ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 1 day 11 hours ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 1 day 23 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 23 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 2 days 11 hours ago Availability of the 2026 Interim Financial Report
